

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Checklist

The CHEERS 2022 statement replaces the 2013 CHEERS statement, which should no longer be used. The CHEERS 2022 checklist contains 28 items with accompanying descriptions. Checklist users should indicate the section of the manuscript where relevant information can be found. The authors recommend using a section heading with a paragraph number. If an item does not apply to a particular economic evaluation, checklist users are encouraged to report "Not Applicable." If information is otherwise not reported, checklist users are encouraged to write, "Not Reported." Users should avoid the term "Not Conducted" as CHEERS is intended to guide and capture reporting. Additional information on CHEERS 2022 can be found [here](#).



Title

1. Title

Identify the study as an economic evaluation and specify the interventions being compared.

"Costeffectiveness" and intervention mentioned in title.

Abstract

2. Abstract

Provide a structured summary that highlights context, key methods, results, and alternative analyses.

The abstract highlights the context of the intervention, the methods, and the results. Only little is mentioned in regards to alternative analyses, but this is described in the methods and results sections respectively.

Introduction

3. Introduction: Background and Objectives

Give the context for the study, the study question, and its practical relevance for decision making in policy or practice.

See Background, pp 3-4

Methods

4. Health economic analysis plan

Indicate whether a health economic analysis plan was developed and where available.

This economic evaluation was conducted retrospectively, and no prespecified health economic analysis plan was formally designed

5. Study population

Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).

See Results, 1. paragraph, p11

6. Setting and location

Provide relevant contextual information that may influence findings.

See Discussion, various paragraphs, pp 15-19

7. Comparators

Describe the interventions or strategies being compared and why chosen.

See Methods/PROKID interventions, paragraph 1-3, pp 6-7

8. Perspective

State the perspective(s) adopted by the study and why chosen.

See Methods/Study design, paragraph 1, p 5

9. Time horizon

State the time horizon for the study and why appropriate.

See Methods/Study design, paragraph 1, p 3

10. Discount rate

Report the discount rate(s) and reason chosen.

See Methods/Outcomes, paragraph 2, p 8

11. Selection of outcomes

Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).

See Methods/Outcomes, pp 7-8

12. Measurement of outcomes

Describe how outcomes used to capture benefit(s) and harm(s) were measured.

See Methods/Outcomes, pp 7-8

13. Valuation of outcomes

Describe the population and methods used to measure and value outcomes.

See Methods/Outcomes, paragraphs 3-4, p 8

14. Measurement and valuation of resources and costs

Describe how costs were valued.

See Methods/Outcomes, paragraphs 1-2, p 7

15. Currency, price date, and conversion

Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.

See Methods/Outcomes, paragraph 2, p 8

16. Rationale and description of model

If modeling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed.

See Methods/Statistical analysis, pp 9-10

17. Analytics and assumptions

Describe any methods for analyzing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.

See Methods/Statistical analysis, pp 9-10

18. Characterizing heterogeneity

Describe any methods used for estimating how the results of the study vary for subgroups.

See Methods/Statistical analysis, pp 9-10

19. Characterizing distributional effects

Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations.

See Methods/Statistical analysis, pp 9-10

20. Characterizing uncertainty

Describe methods to characterize any sources of uncertainty in the analysis.

See Methods/Statistical analysis, pp 9-10

21. Approach to engagement with patients and others affected by the study

Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (eg, clinicians or payers) in the design of the study.

Not reported. Patient involvement is described in the trial

Results

22. Study parameters

Report all analytic inputs (eg, values, ranges, references) including uncertainty or distributional assumptions.

See Methods/Statistical analysis, pp 9-10

23. Summary of main results

Report the mean values for the main categories of costs and outcomes of interest and summarize them in the most appropriate overall measure.

Results, pp 11-12

24. Effect of uncertainty

Describe how uncertainty about analytic judgments, inputs, or projections affects findings. Report the effect of choice of discount rate and time horizon, if applicable.

Discussion, paragraph 4, p 16

25. Effect of engagement with patients and others affected by the study

Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study.

Not reported. Patient involvement is described in the trial

Discussion

26. Study findings, limitations, generalizability, and current knowledge

Report key findings, limitations, ethical, or equity considerations not captured and how these could impact patients, policy, or practice.

..Discussion, paragraph 4 & 8, pp 16, 18

Other Relevant Information

27. Source of funding

Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis.

See Declarations/Funding, p 22

28. Conflicts of interest

Report authors' conflicts of interest according to journal or International Committee of Medical Journal Editors requirements.

See Declarations/Competing interests, p 21
